Avestar Capital’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$456K Buy
+2,369
New +$255K 0.04% 379
2024
Q3
– Sell
-2,495
Closed -$296K – 491
2024
Q2
$296K Buy
2,495
+608
+32% +$76.9K 0.03% 334
2024
Q1
$201K Buy
+1,887
New +$190K 0.02% 428
2022
Q3
– Sell
-307
Closed -$44K – 305
2022
Q2
$44K Buy
+307
New +$43.9K 0.01% 280
2022
Q1
– Sell
-5,438
Closed -$916K – 440
2021
Q4
$1.38M Sell
5,438
-844
-13% -$247K 0.17% 129
2021
Q3
$2.42M Sell
6,282
-3,421
-35% -$1.26M 0.31% 70
2021
Q2
$2.28M Buy
9,703
+184
+2% +$32.9K 0.31% 85
2021
Q1
$1.7M Buy
9,519
+1,238
+15% +$179K 0.38% 47
2020
Q4
$865K Buy
8,281
+3,340
+68% +$338K 0.24% 79
2020
Q3
$347K Buy
+4,941
New +$344K 0.11% 146

Other funds holding MRNA

Avestar Capital's MRNA Position: Q3 2026 in Review

Avestar Capital opened a new position in Moderna (MRNA) in Q3 2026: 2,369 shares worth $456K. The stake represents 0.04% of the portfolio and ranks #379 among its holdings. This is a return to the name: Avestar Capital previously reported a position in MRNA as recently as Q2 2024.

Avestar Capital first reported a position in MRNA in Q3 2020 and has held it in 10 quarters since. The position peaked at $2.42M in Q3 2021. 1,044 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Avestar Capital held 2,369 shares of Moderna worth $456K as of Q3 2026.
  • Moderna was a new Avestar Capital position in Q3 2026.
  • Moderna made up 0.04% of Avestar Capital's portfolio in Q3 2026, its #379 holding.
  • Avestar Capital first reported a position in Moderna in Q3 2020 and has held it in 10 quarters since.
  • Avestar Capital's Moderna position peaked at $2.42M in Q3 2021.
  • 1,044 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Avestar Capital's 13F filing for Q3 2026, filed 28 Oct 2026.